Profound Medical Corp. (PROF) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, PROF scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 7/20 (ROIC of -35% and FCF yield of -17.93%), indicating the business is not currently generating returns on capital or free cash. Whale 13F Flow scores 6/20, reflecting institutional accumulation and options positioning that the rating treats as weak support. Insider Conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar in the set. Macro Regime Fit scores 6/20 with a beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet is the strongest pillar at 14/20, citing an Altman Z-Score of 5.97, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 0.07.

For a prospective investor, the practical reading is that the balance sheet is the main source of comfort, while cash burn, negative returns, and weak insider signals are the main concerns. Upside drivers in the source data are limited to the recent news flow and the market-level catalysts described below; valuation cannot be assessed because earnings-based multiples are not available in source data. The rating is an analytical framework output, not a recommendation, and its components should be weighed against the financial trend and open questions that follow.

Per the SEC financials, revenue rose from $5.9M in FY 2023 to $16.1M in FY 2025, while operating losses widened from $-28.7M to $-41.3M over the same span. Operating and net margins are both reported at -60% per the market data, and ROIC is -35%. The Roarable RQD rating records an Altman Z-Score of 5.97, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 0.07, which together describe a lightly levered balance sheet even as cash consumption remains heavy. Cash of $59.7M against reported debt of $4.5M at FY 2025 reflects the funding base, though the trajectory of burn is the central question.

Six news items are listed for PROF. Headlines reference a Q3 revenue beat and a raised Q3 revenue outlook, with one wire describing a stock move of 20% on that outlook and another describing a 17.1% pre-market surge amid a broader market move. Several items reference analyst-expectation upside figures of 58.77% and 89.93%, reported by Yahoo Finance; these are presented in the headlines and are not corroborated by the analyst data section. One Stock Titan item notes gross margin is expected to top 70% in the preliminary Q3 revenue preview, flagged as a market-wire item rather than a catalyst. Per the news feed, all items are tagged to PROF; no other proprietary signals are present. Risk watch items include the dependence of the upside narrative on preliminary and outlook-based revenue figures, and the absence of full Q3 financials in source data.

• What drove the step-up in FY 2025 revenue to $16.1M, and how durable is that revenue base?
• What is the path to narrowing the operating loss of $-41.3M, given cash of $59.7M and FCF of $-38.4M?
• What are the Q3 revenue figures in full, and do they confirm the preliminary outlook referenced in the news feed?
• What do the analyst price targets and consensus ratings look like, given the analyst data is absent from source data?
• What do insider and institutional holdings show, given the holders data and Congressional PTR flow are not available in source data?